{"id":949412,"date":"2026-04-07T09:31:33","date_gmt":"2026-04-07T13:31:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/"},"modified":"2026-04-07T09:31:33","modified_gmt":"2026-04-07T13:31:33","slug":"akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/","title":{"rendered":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., April  07, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=olhwk9xFn4kMjY12HSbm1USS_jPo3MSNs_76MRjVKqrEFaIbQiPXQEbtwJEFQDd5DZkZNDZxbvrtNUSlUZLIqTn9EPA_8DOLQmFtUx2gzpo=\" rel=\"nofollow\" target=\"_blank\"><u>Akebia Therapeutics<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cog9FHMRph4rctGuEEkXC40_H9HLDUDNsfUECcUBpret2Y2WSCxWz5n_JYcSko-J5JDCSSeBYGUY-FnUaYGRxA==\" rel=\"nofollow\" target=\"_blank\"><sup><u>\u00ae<\/u><\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8xPfbGKGMawy7yZ4SGC5ZXcmngoGp3pPUUdx_X2LKlKgzoh4aRBn5wQ3s27qwhxcg9D28ZeEZYjjWVDkArBuAg==\" rel=\"nofollow\" target=\"_blank\"><u>, Inc.<\/u><\/a> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium.<\/p>\n<p align=\"justify\">During meetings, management will discuss its commercial products, and data and other information shared during Akebia\u2019s recent R&amp;D Day that showcased its robust pipeline of clinical stage kidney disease programs.<\/p>\n<p>\n        <strong>About Akebia Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-5X0nd2wOaLqtW9QolAY8YFfZnbix2GNIIN1S3SLUbzTBzSiczskuZ4BbM-XkmhZv5nS9zhD8nnHFu6BKLuFow==\" rel=\"nofollow\" target=\"_blank\">www.akebia.com<\/a>, which does not form a part of this release.<\/p>\n<p>\n        <strong>Akebia Therapeutics Contact<\/strong><br \/>\n        <br \/>Mercedes Carrasco<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hJTgxW7lpiRkPteWB-YDWULrC0ofIOMqGFpsZkVihLyaBH3Qs6qt-Q1v9v9J5fY-w__eRpi95LmhGLW_ZbzyHwrNrM6R4ZyrMeYQ5aZCCNY=\" rel=\"nofollow\" target=\"_blank\">mcarrasco@akebia.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDcxN2U5MzktY2U0OS00ZjQwLWEyNzktNDZkMDQwYzZjNTI5LTEwMTc5MjgtMjAyNi0wNC0wNy1lbg==\/tiny\/Akebia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Akebia Therapeutics\u00ae, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium. During meetings, management will discuss its commercial products, and data and other information shared during Akebia\u2019s recent R&amp;D Day that showcased its robust pipeline of clinical stage kidney disease programs. About Akebia Therapeutics Akebia Therapeutics, Inc. is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Akebia Therapeutics\u00ae, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium. During meetings, management will discuss its commercial products, and data and other information shared during Akebia\u2019s recent R&amp;D Day that showcased its robust pipeline of clinical stage kidney disease programs. About Akebia Therapeutics Akebia Therapeutics, Inc. is a &hellip; Continue reading &quot;Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:31:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium\",\"datePublished\":\"2026-04-07T13:31:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/\"},\"wordCount\":187,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/\",\"name\":\"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\",\"datePublished\":\"2026-04-07T13:31:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) &#8212; Akebia Therapeutics\u00ae, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium. During meetings, management will discuss its commercial products, and data and other information shared during Akebia\u2019s recent R&amp;D Day that showcased its robust pipeline of clinical stage kidney disease programs. About Akebia Therapeutics Akebia Therapeutics, Inc. is a &hellip; Continue reading \"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-07T13:31:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium","datePublished":"2026-04-07T13:31:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/"},"wordCount":187,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/","name":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=","datePublished":"2026-04-07T13:31:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDg5MyM3NTIxOTUzIzIwMDYzNTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}